Clinical Trial

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-02-09; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03050190
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions B-cell Malignancies
Enrollment 200 participants
Start Date 2025-05-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23